EcoDrugPlus

Adenosine A2a Receptor

Ensembl ID : ENSNBRG00000020331
Gene Symbol: ADORA2A
3 Cross references
198 Possible Orthologues:

Adenosine A2a Receptor A

Ensembl ID : ENSNBRG00000010557
Gene Symbol: ADORA2AA
1 Cross references
189 Possible Orthologues:

Adenosine Deaminase-Like

Ensembl ID : ENSNBRG00000000782
Gene Symbol: LOC102776391
3 Cross references
216 Possible Orthologues:

Adenosine Receptor A1-Like

Ensembl ID : ENSNBRG00000008303
Gene Symbol: LOC102786016
2 Cross references
135 Possible Orthologues:

Adenosine Receptor A1-Like

Ensembl ID : ENSNBRG00000009081
Gene Symbol: LOC102789184
3 Cross references
173 Possible Orthologues:

Adenosine Receptor A2b-Like

Ensembl ID : ENSNBRG00000015127
Gene Symbol: LOC102779092
3 Cross references
199 Possible Orthologues:

Adrenoceptor Alpha 1b

Ensembl ID : ENSNBRG00000018075
Gene Symbol: ADRA1B
1 Cross references
194 Possible Orthologues:

Adrenoceptor Alpha 1d

Ensembl ID : ENSNBRG00000014484
Gene Symbol: ADRA1D
3 Cross references
194 Possible Orthologues:

Adrenoceptor Alpha 2a

Ensembl ID : ENSNBRG00000003476
Gene Symbol: ADRA2A
1 Cross references
176 Possible Orthologues:

Adrenoceptor Alpha 2a

Ensembl ID : ENSNBRG00000017081
Gene Symbol: ADRA2A
3 Cross references
159 Possible Orthologues:

Adrenoceptor Alpha 2b

Ensembl ID : ENSNBRG00000017684
Gene Symbol: ADRA2B
1 Cross references
174 Possible Orthologues:

Adrenoceptor Alpha 2c

Ensembl ID : ENSNBRG00000021459
Gene Symbol: ADRA2C
4 Cross references
157 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).